CD274 and non-small cell lung carcinoma: Platelet expression of the co-inhibitory immune checkpoint, PD-L1, acquired via transfer from tumor cells, has also been identified as another mechanism of immunosuppression that is operative in NSCLC, as well as being an impediment to co-inhibitory immune-checkpoint-targeted therapy [74].